| Trial Identifier: | D8111C00003 |
| Sponsor: | AstraZeneca |
| Collaborator: |
R-Pharm
The Russian Direct Investment Fund (RDIF)
The Gamaleya National Center of Epidemiology & Microbiology
|
| NCTID:: | NCT04684446 |
| Start Date: | August 2021 |
| Primary Completion Date: | April 2022 |
| Study Completion Date: | April 2022 |
| Condition: | COVID-19 Immunisation |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
| Country | Location |
|---|---|
| Belarus | Vitebsk, Belarus, 210037 |
| Russian Federation | Moscow, Russian Federation, 115419 |
| Russian Federation | Moscow, Russian Federation, 109240 |
| Russian Federation | Moscow, Russian Federation, 121359 |
| Russian Federation | Saint-Petersburg, Russian Federation, 197376 |
| Russian Federation | Saint-Petersburg, Russian Federation, 196158 |
| Russian Federation | St. Petersburg, Russian Federation, 197022 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company